Table 2 Univariate analysis of PTB patients with pulmonary fungal coinfection (training dataset, N = 214)
Variable | Case group (n = 102) | Control group (n = 112) | X2 /Fisher | P |
|---|---|---|---|---|
Age [n(%)] | Â | Â | 3.893 | 0.048 |
 > 65 years old | 32 (31.4) | 22 (19.6) |  |  |
 ≤ 65 years old | 70 (68.6) | 90 (80.4) |  |  |
Gender [n(%)] | Â | Â | 0.492 | 0.483 |
Male | 76 (74.5) | 88 (78.6) | Â | Â |
Female | 26 (25.5) | 24 (21.4) | Â | Â |
Address [n(%)] | Â | Â | Â | 0.483 |
North | 97 (95.1) | 109 (97.3) | Â | Â |
South | 5 (4.9) | 3 (2.7) | Â | Â |
Smoke [n(%)] | Â | Â | 2.401 | 0.121 |
Yes | 48 (47.1) | 41 (36.6) | Â | Â |
No | 54 (52.9) | 71 (63.4) | Â | Â |
Drink [n(%)] | Â | Â | 0.016 | 0.898 |
Yes | 32 (31.4) | 35 (31.3) | Â | Â |
No | 70 (68.6) | 77 (68.7) | Â | Â |
Category [n(%)] | Â | Â | 6.187 | 0.013 |
Initial | 20 (19.6) | 39 (34.8) | Â | Â |
Recurrent | 82 (80.4) | 73 (65.2) | Â | Â |
Drug resistance [n(%)] | Â | Â | 3.999 | 0.135 |
No drug resistance | 82 (80.4) | 96 (85.7) | Â | Â |
Single drug resistance | 12 (11.8) | 5 (4.5) | Â | Â |
Other drug resistance | 8 (7.8) | 11 (9.8) | Â | Â |
Illness course [n(%)] |  |  | 23.067 |  < 0.001 |
 ≤ 1 year | 34 (33.3) | 70 (62.5) |  |  |
 > 1 year, ≤ 5 years | 32 (31.4) | 27 (24.1) |  |  |
 > 5 years, ≤ 10 years | 11 (10.8) | 8 (7.1) |  |  |
 > 10 years | 25 (24.5) | 7 (6.3) |  |  |
Pulmonary cavitation [n(%)] |  |  | 15.043 |  < 0.001 |
Yes | 74 (72.5) | 52 (46.4) | Â | Â |
No | 28 (27.5) | 60 (53.6) | Â | Â |
Pleural effusion [n(%)] | Â | Â | 4.966 | 0.026 |
Yes | 47 (46.1) | 35 (31.3) | Â | Â |
No | 55 (53.9) | 77 (68.7) | Â | Â |
Regular anti-tuberculosis [n(%)] | Â | Â | 2.163 | 0.141 |
Yes | Â | Â | Â | Â |
No | 63 (52.1) | 58 (51.8) | Â | Â |
| Â | 39 (41.9) | 54 (48.2) | Â | Â |
Broad-spectrumAdvanced antibiotics were used for at leastlest 1 week [n(%)] |  |  | 39.314 |  < 0.001 |
Yes | 65 (63.7) | 12 (21.4) | Â | Â |
No | 37 (36.3) | 24 (78.6) | Â | Â |
Glucocorticoid were used for at leastlest 2Â weeks [n(%)] | Â | Â | 2.698 | 0.1 |
Yes | 19 (18.6) | 12 (10.7) | Â | Â |
No | 83 (81.4) | 100 (89.3) | Â | Â |
Chemotherapy or immunosuppressants [n(%)] | Â | Â | Â | 0.007 |
Yes | 9 (8.8) | 1 (0.9) | Â | Â |
No | 93(91.2) | 111(99.1) | Â | Â |
Invasive operation [n(%)] | Â | Â | 0.556 | 0.456 |
Yes | 69 (67.6) | 81 (72.3) | Â | Â |
No | 33 (32.4) | 31 (27.7) | Â | Â |
Surgery [n(%)] | Â | Â | 5.609 | 0.018 |
Yes | 47 (46.1) | 34 (30.4) | Â | Â |
No | 55 (53.9) | 78 (69.6) | Â | Â |
Bacterial pneumoniaBacterial infection in the lungs [n(%)] |  |  | 21.051 |  < 0.001 |
Yes | 24 (23.5) | 3 (2.7) | Â | Â |
No | 78 (76.5) | 109 (97.3) | Â | Â |
Chronic bronchitis/ COPD/BronchiectasisBronchitis/Asthma [n(%)] | Â | Â | 5.266 | 0.022 |
Yes | 19 (18.6) | 9 (8.0) | Â | Â |
No | 83 (81.4) | 103 (92.0) | Â | Â |
Silicosis [n(%)] | Â | Â | Â | 0.107 |
Yes | 3 (2.9) | 0 (0) | Â | Â |
No | 99 (97.1) | 112 (100) | Â | Â |
Interstitial lung disease [n(%)] | Â | Â | Â | 1 |
Yes | 3 (3.9) | 4 (3.6) | Â | Â |
No | 99 (97.1) | 108 (96.4) | Â | Â |
Hepatic injuryHypohepatia [n(%)] | Â | Â | 1.82 | 0.177 |
Yes | 37 (36.3) | 31 (27.7) | Â | Â |
No | 65 (63.7) | 81 (72.3) | Â | Â |
Renal inadequacy [n(%)] | Â | Â | 0.208 | 0.648 |
Yes | 8 (6.29) | 7 (4.90) | Â | Â |
No | 94 (93.71) | 105 (95.10) | Â | Â |
Tumor / Hematological disease [n(%)] | Â | Â | 3.808 | 0.051 |
Yes | 9 (8.8) | 3 (2.7) | Â | Â |
No | 93 (91.2) | 109 (97.3) | Â | Â |
Hypoproteinemia [n(%)] |  |  | 30.289 |  < 0.001 |
Yes | 56 (54.9) | 21 (17.9) | Â | Â |
No | 46 (45.1) | 91 (81.2) | Â | Â |
Anemia [n(%)] |  |  | 14.107 |  < 0.001 |
Yes | 42 (41.2) | 20 (17.9) | Â | Â |
No | 60 (58.8) | 92 (82.1) | Â | Â |
Diabetes [n(%)] | Â | Â | 0.044 | 0.834 |
Yes | 24 (23.5) | 25 (22.3) | Â | Â |
No | 78 (76.5) | 87 (77.7) | Â | Â |